Straatmijer, Tessa http://orcid.org/0000-0001-6989-5226
Biemans, Vince B. C.
Moes, Dirk Jan A. R.
Hoentjen, Frank
ter Heine, Rob
Maljaars, P. W. Jeroen
Theeuwen, Rosaline
Pierik, Marieke
Duijvestein, Marjolijn
van der Meulen-de Jong, Andrea E.
,
Article History
Received: 25 July 2022
Accepted: 1 January 2023
First Online: 15 March 2023
Declarations
:
: TS, VBC, RT: none. MD: reports advisory fees from Echo Pharma and Robarts Clinical Trials, Inc., speaker fees from Janssen, Merck & Co., Inc., Pfizer, Takeda and Tillotts Pharma, and nonfinancial support from Dr. Falk Pharm. FH has served on advisory boards or as speaker for Abbvie, Janssen-Cilag, MSD, Takeda, Celltrion, Teva, Sandoz and Dr Falk Funding (Grants/Honoraria): Takeda, Janssen-Cilag, Abbvie Consulting Fees: Celgene. MP has served on advisory boards, or as speaker or consultant for Abbvie, Janssen‐Cilag, MSD, Takeda, Ferring, Dr Falk, and Sandoz and has received unrestricted grants from Janssen‐Cilag, Abbvie and Takeda outside the submitted work. AE van der Meulen has received a presentation fee from Janssen and served on the advisory board of Takeda and Galapagos, outside of the submitted work.